Article

Anti-Obesity Drugs and Bariatric Surgery

William Encinosa, Dongyi (Tony) Du and Didem Bernard

in The Oxford Handbook of the Social Science of Obesity

Published in print October 2011 | ISBN: 9780199736362
Published online September 2012 | | DOI: http://dx.doi.org/10.1093/oxfordhb/9780199736362.013.0045

Series: Oxford Handbooks

 Anti-Obesity Drugs and Bariatric Surgery

More Like This

Show all results sharing these subjects:

  • Economics
  • Health, Education, and Welfare

GO

Show Summary Details

Preview

This chapter describes the startlingly good outcomes associated with bariatric surgery, such as rapid improvement or even resolution of high blood pressure and Type II diabetes in almost all patients, and decreased mortality relative to a control group that is morbidly obese but did not get surgery. There are two main types of prescription drugs approved by the U.S. Food and Drug Administration for treating obesity: appetite suppressants and lipase inhibitors. There is significant weight loss under bariatric surgery, which results in much more weight loss and reduction in co-morbidities (e.g., diabetes) and mortality than bariatric medications. The potential move to endoscopically placed gastric devices is based on research which shows that many of the benefits of gastric bypass, such as immediate mitigation of diabetes, is due to a change in gut peptide release, not a reduction in food intake.

Keywords: bariatric surgery; high blood pressure; Type II diabetes; mortality; obesity; appetite suppressants; lipase inhibitors

Article.  7044 words. 

Subjects: Economics ; Health, Education, and Welfare

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.